Sub-set analyses outcomes from the BEST-CLI trial shows glomerular filtration rates directly correlate to mortality and major adverse limb events in chronic limb-threatening ischemia (CLTI) patients, especially those on dialysis, and suggests endovascular therapy is associated with lower mortality but an increased rate of reintervention compared to surgical treatment in CLTI patients.

Dr Alik Farber (Boston University School of Medicine, Boston, US) joins us to discuss the sub-set analyses completed by 30 global working groups using data from the prospective, randomised, multicentre BEST-CLI trial (NCT02060630; Carelon Research). BEST-CLI aimed to investigate the effectiveness of the best available surgical treatment verses best available endovascular treatment for patients with CLTI. Dr Farber highlights some of the main investigations and reveals the outcomes from one analysis assessing the effect of CKD in patients with CLTI. Once the analyses are completed, there will be approximately 40 sub-group investigations.

Interview Questions:
1. What is the reasoning behind the BEST-CLI sub-set analyses?
2. What were some of the study designs and patient populations for the analyses?
3. Are there any key take-aways from the analyses that you want to highlight?
4. Did these analyses highlight any further research needed in these areas?

Recorded remotely from Boston, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: David Ben-Harosh, Oliver Miles, Tom Green

Support: This is an independent interview produced by Radcliffe Vascular.